Technical Analysis for CYTX - Cytori Therapeutics Inc

Grade Last Price % Change Price Change
grade D 0.325 6.56% 0.02
CYTX closed up 6.56 percent on Friday, January 18, 2019, on 1.31 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical CYTX trend table...

Date Alert Name Type % Chg
Jan 18 20 DMA Support Bullish 0.00%
Jan 18 Crossed Above 50 DMA Bullish 0.00%
Jan 17 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 6.56%
Jan 17 20 DMA Support Bullish 6.56%
Jan 16 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 4.50%
Jan 16 20 DMA Support Bullish 4.50%
Jan 15 20 DMA Support Bullish 6.56%
Jan 14 50 DMA Resistance Bearish 6.91%
Jan 14 20 DMA Support Bullish 6.91%
Jan 14 Outside Day Range Expansion 6.91%

Older signals for CYTX ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Cytori Therapeutics, Inc., a cell therapy company, engages in developing cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular diseases and other medical conditions. It primarily provides the Celution System, which automates the process of digesting fat tissue, releasing the ADRCs. It also offers the StemSource Cell Bank, a suite of products to allow hospitals or tissue banks to cryopreserve adipose-derived stem and regenerative cells; and StemSource 900/MB, a research laboratory equipment, as well as a range of ancillary products designed to optimize tissue harvest and graft delivery. Its products also include Celution 800 System that has CE Mark approval for certain soft tissue procedures, such as breast reconstruction, tissue ischemia, deficiency or injury of skin, fat, and muscle and fascia, as well as soft tissue wounds or fistulae associated with trauma, diabetes, ischemia, and radiation injury. The company markets its systems, instrumentations, and consumables directly, as well as through a network of distributors to hospitals, plastic surgery clinics, tissue banks, and stem cell banking companies, as well as researchers performing investigator-initiated and funded studies worldwide. Cytori Therapeutics, Inc. was founded in 1996 and is headquartered in San Diego, California.
Is CYTX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 5.18
52 Week Low 0.25
Average Volume 233,326
200-Day Moving Average 1.1138
50-Day Moving Average 0.3203
20-Day Moving Average 0.3052
10-Day Moving Average 0.314
Average True Range 0.0266
ADX 15.58
+DI 15.07
-DI 16.254
Chandelier Exit (Long, 3 ATRs ) 0.2562
Chandelier Exit (Short, 3 ATRs ) 0.3298
Upper Bollinger Band 0.339
Lower Bollinger Band 0.2714
Percent B (%b) 0.79
BandWidth 22.14941
MACD Line -0.0016
MACD Signal Line -0.0039
MACD Histogram 0.0023
Fundamentals Value
Market Cap 11.29 Million
Num Shares 34.7 Million
EPS -1.00
Price-to-Earnings (P/E) Ratio -0.32
Price-to-Sales 1.71
Price-to-Book 1.28
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.37
Resistance 3 (R3) 0.37 0.35 0.36
Resistance 2 (R2) 0.35 0.33 0.35 0.36
Resistance 1 (R1) 0.34 0.33 0.34 0.34 0.36
Pivot Point 0.32 0.32 0.32 0.32 0.32
Support 1 (S1) 0.31 0.30 0.31 0.31 0.29
Support 2 (S2) 0.29 0.30 0.29 0.29
Support 3 (S3) 0.28 0.29 0.29
Support 4 (S4) 0.28